Our partners often compliment us on our global network as one of our key strengths and unique capabilities. CRT's ability to bring together academic research and industrial partners from different parts of the world has been well illustrated through a wide variety of deals - from the collaboration with Merck Serono, the ICR and University of Cardiff focused on the discovery of WNT inhibitors, to the more recent collaboration between the University of Auckland and CRT’s own Discovery Laboratories that are focused on developing a new anti-cancer drug.
Most recently, our subsidiary CRT Inc, located in Boston US, led in a recent agreement with Bayer-Schering Pharma based in Germany. Under the agreement, Bayer Schering will evaluate new leptin antagonist peptides as potential experimental treatments initially in the area of gynaecological diseases, including cancer.
The leptin antagonists were first developed at the Boston Biomedical Research Institute (BBRI) - an independent nonprofit institute dedicated to basic biomedical research in the USA - by Drs. Paul Leavis and Ruben Gonzalez, who have shown that the peptides are effective in blocking the effects of leptin in several diseases.
Cancer Research Technology - through CRT Inc – have agreed with BBRI to market and commercialise the technology and have provided additional funding to BBRI for further development of the inhibitors. The agreement with Bayer Schering Pharma represents the successful outcome of these activities and the close working relationships between CRT Inc and its research partners the international community of industrial partners.